AVITA Medical, Inc. (NASDAQ: RCEL) reported Q2 EPS of ($0.41), $0.10 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $11.75 million versus the consensus estimate of $11.3 million.

GUIDANCE:

AVITA Medical, Inc. sees Q3 2023 revenue of $13-14 million.

For earnings history and earnings-related data on AVITA Medical, Inc. (RCEL) click here.